Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Clears Pradaxa For Stroke Prevention, Rejects Appeal By NHS Budget Holders

This article was originally published in The Pink Sheet Daily

Executive Summary

Following a failed appeal by regional NHS payers worried about its cost, Boehringer Ingelheim's Pradaxa is finally recommended by the U.K.'s cost watchdog, NICE, for preventing stroke associated with atrial fibrillation.

You may also be interested in...



NICE Clears Pradaxa For DVT, Setting Up Another Clash With Xarelto

NICE has given the thumbs up to Boehringer Ingelheim's Pradaxa in deep vein thrombosis and pulmonary embolism, which means the drug is now set to battle Bayer's Xarelto for market share in this indication.

Xarelto, Pradaxa Difficult To Separate After Positive NICE Final Guidance

Bayer’s Xarelto has made it into the NHS in England after its NICE recommendation went unchallenged, prompting a head to head battle with Boehringer Ingelheim’s Pradaxa.

European HTA Highlights: Discounts Soften NICE Approach But Germany’s IQWiG Shows Its Teeth

It is becoming ever more clear that the overriding factor in NICE’s decision-making process is a desire to see cost-effectiveness, irrespective of the clinical benefit of a drug. But in Germany, companies are challenged by IQWiG’s tightened-up, science-based review system.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel